A case of acute renal failure with COVID-19 under Molnupiravir treatment

Hasan Esat Yücel 1*

1 Ahi Evran University, Faculty of Medicine, Department of Internal medicine, Kirsehir, TR

* Corresponding Author: Hasan Esat Yücel E-mail: drh.esat@hotmail.com

ABSTRACT

Objective: Diarrhea, nausea, and vomiting are the most commonly reported mild side effects of Molnupiravir. However, this case shows that it may indirectly cause acute renal failure.

Case: 67-Year-old male patient diagnosed with hypertension and chronic obstructive pulmonary disease developed severe nausea, vomiting, and diarrhea with the use of drugs. In the patient’s examinations, severe deterioration in kidney functions occurred. The patient who developed acute tubular necrosis was taken to hemodialysis twice. Intravenous hydration and supportive treatments were started. In the follow-up, clinical and renal functions improved. In patients over 65 years of age and with comorbidities, the adverse effects of Molnupiravir should be considered and followed closely.

Keywords: COVID-19, SARS-COV-2, Molnupiravir, Diarrhea, Renal Failure

INTRODUCTION

Positive developments have been achieved with vaccination and anti-viral treatments against Coronavirus disease 2019 (COVID-19). Since the RNA-Dependent RNA-Polymerase (RdRp) enzyme plays an important role in the replication of the Severe acute Respiratory Syndrome Virus (SARS-COV-2), it is important for antiviral treatment targets (1, 2).

Favipiravir and Remdesivir are RdRp inhibitors and have been approved for treatment. Both drugs have been shown to reduce clinical symptoms and slow down progression (3,4).

However, an alternative treatment has been sought because there are only intravenous (IV) forms of Remdesivir and its weak pharmacokinetic efficacy in Favipiravir. Recently, orally available Molnupiravir has been promising due to its tolerability and positive efficacy profile. It suppressed the replication of SARS-COV-2 through inhibition of RdRp and attracted great attention by providing a rapid and effective reduction in viral load. It was developed by scientists at Emory University (USA) (5,6).

Phase-1 and 2 studies have been completed(7,8). However, Phase-3 studies are still in progress, and the efficacy, tolerability, and safety profile remain unclear(9). This case report aims to present a clinical case infected with SARS-CoV-2, who developed severe nausea, vomiting, and diarrhea with Molnupiravir treatment and progressed to severe acute renal failure (ARF) during follow-up.

CASE

A 67-year-old male patient with hypertension and chronic obstructive pulmonary disease diagnosed for 10 years, regularly uses Perindopril/Indapamide (10/2,5mg/day) tablet (TB), metoprolol (50 mg/day) tb, formoterol-budenoside 400 µg/day inhaler (inh), tiotrportun bromide (inh) drugs. The patient, who had been Synovac vaccinated 3 times before, applied to the Kirsehir Training and Research Hospital pandemic emergency on 17.02.2022 with complaints of fever, weakness, fatigue, sweating, and myalgia. There were no complaints of nausea, vomiting, or diarrhea at admission.

Due to patient's clinical status was good, laboratory examination and direct X-ray/thorax CT were not taken from the patient. Infection positivity has been checked with Polymerase Chain Reaction (PCR) test. SARS-COV-2-Omicron variant positivity has been detected. On 18.02.2022, Molnupiravir 200 mg tablet (TB) was started as 2x800 mg outpatient treatment by the healthcare teams.
Molnupiravir was used regularly for 5 days. He continued to his own previous drugs as well. During this time, he received only paracetamol TB as an analgesic. He did not use non-steroidal anti-inflammatory. However, the patient had severe nausea, vomiting, and diarrhea 15-20 times a day with the use of Molnupiravir. Oral intake is impaired. He could not provide fluid hydration. Diarrhea disappeared after the medication was discontinued, but complaints of nausea, vomiting, and loss of appetite persisted. He applied to the emergency department on 07.03.2022 with these complaints. Fever: 36.1°C; Pulse: 106/minute; Blood Pressure: 90/60 mmHg; Respiratory rate: 18/minute; oxygen saturation (SpO2): % 96. His general condition was poor; he had a sluggish and tired appearance. He was re-evaluated for SARS-COV-2 infection. PCR test was negative. Pneumonia or any focus of infection was not detected. In the examinations of the patient at the time of admission to the emergency department, urea: 190mg/dl; Blood urea nitrogen (BUN):89 mg/dl; Creatinine (CRE): 8.9 mg/dl; GFR: 5 ml/min; Sodium (Na): 136 mmol/l; Potassium (K): 4.8 mmol/l; It came as Calcium (Ca): 9 mmol/l; phosphorus(P): 5.5 mmol/l. Disease Epidemiology Cooperation (CKD-EPI) formula (10). There was severe metabolic acidosis in venous blood gas. Ph: 7.17, PCO2:39 mmHg, PO2: 15.2 mmHg, HCO3-std:13.1 meq/l; Lactate(mmol/l):0.7 detected (Table-2).

Nephrotoxic agents avoided. After the first dialysis, he was taken to HD for a second time for another 4 hours, as uremia and acidosis continued at a serious rate in his control examinations (Tables-1 and 2). UF is not done again. In terms of aetiology, urinary system USG was performed. The parenchymal echogenicity of both kidneys was observed as grade-1 increased (Table-3).

In the follow-ups, the patient's clinic tended to improve. Urine output was about 70-80 cc per hour. He was followed up without dialysis. Anti-hypertensive drugs were not used during the hospitalization. Blood pressures remained stable. Renal functions (Table-1) and proteinuria returned to normal (Table-3). Haemodialysis and urinary catheters were removed. He was discharged with recommendations.

### Table 1. Changes in the patient's kidney function tests and complete blood count

| Variables          | First day | Second day | Third day | Fourth day | Fifth day | Sixth day | Seventh day |
|--------------------|----------|------------|-----------|------------|-----------|-----------|-------------|
| Urea (mg/dL)       | 190      | 153        | 123       | 103        | 75        | 59        | 32          |
| BUN (mg/dL)        | 89       | 71         | 57        | 48         | 35        | 28        | 15          |
| CRE (mg/dL)        | 8.9      | 7          | 3.13      | 1.78       | 1.42      | 1.31      | 1.04        |
| GFR (ml/min)       | 5        | 7          | 20        | 39         | 51        | 56        | 74          |
| Na (mmol/L)        | 136      | 137        | 137       | 139        | 142       | 141       | 140         |
| K (mmol/L)         | 5        | 4.3        | 4.2       | 4.1        | 3.8       | 4.3       | 4           |
| Ca (mmol/L)        | 9        | 8.4        | 8.4       | 8.3        | 8.1       | 7.8       | 7.9         |
| P (mmol/L)         | 5.5      | 5.3        | 4         | 3.5        | 3         | 3         | 3.2         |
| WBC (10³/µL)       | 10,01    | 8,89       | 9,58      | 10,81      | 13,05     | 10,57     | 8,55        |
| Hgb (g/dL)         | 14.9     | 13         | 11.6      | 11.6       | 11.3      | 11.2      | 11.1        |
| Hct %              | 47       | 39,9       | 34,7      | 35,1       | 34        | 34,4      | 32,9        |
| MCV (fl)           | 92.9     | 90.7       | 89        | 88         | 89.9      | 89.4      | 88.4        |
| MCH                | 29.4     | 29.5       | 29.7      | 29.1       | 29.9      | 29.1      | 29.8        |
| PLT (10³/µL)       | 281      | 236        | 185       | 190        | 193       | 204       | 222         |

BUN:Blood Urea Nitrogen;Cre:Creatinine;GFR:Glomerular Filtration Rate; Na:Sodium,K:potassium, Ca:calcium ;P: phosphorus,;WBC:White Blood Cell; Hgb:Hemoglobin;Hct: hematocrit;Plt: Platelet; MCV: Mean Corpuscular Volume;MCH: Mean Corpuscular Hemoglobin

### Table 2. Changes in the patient’s venous blood gas

| Venous Blood Gas Variables | First day | Second day | Third day | Fourth day | Seventh day |
|---------------------------|----------|------------|-----------|------------|-------------|
| pH                        | 7.17     | 7.19       | 7.40      | 7.46       |             |
| PO2 (mmHg)                | 15.2     | 16.3       | 43.4      | 24.6       |             |
| PCO2 (mmHg)               | 39.7     | 40.9       | 29.2      | 37.2       |             |
| HCO3-std (meq/L)          | 13.1     | 13.3       | 19.9      | 25.9       |             |
| Lactate(mmol/L)           | 0.7      | 0.5        | 0.5       | 0.8        |             |
| SpO2 (%)                  | 26       | 38         | 62        | 68         |             |

pH: potential hydrogen; PO2: partial oxygen; PCO2: partial carbon dioxide; HCO3-std: standard bicarbonate; SpO2: Oxygen saturation
DISCUSSION

Nausea, vomiting, and diarrhea developed as side effects of Molnupiravir in the patient. As a result, dehydration occurred. This may be due to the SARS-CoV-2 infection itself. However, the patient did not have these symptoms when he was diagnosed with COVID-19. It started with the use of medication, and the patient's diarrhea regressed after the treatment was completed. In a randomized study by Bernal et al. on outpatients using Molnupiravir, the most frequently reported side effects were diarrhea, nausea, and dizziness. Painter et al. also reported that the most common side effect of Molnupiravir is diarrhea in a placebo-controlled study (11,7).

Continuation of anti-hypertensive drugs together with these side effects, caused hypotension and hypovolemia, which leading to severe renal perfusion failure.

The patient applied to the emergency department approximately 10 days later, although the use of the medication ended and his complaints continued. Because of this delay in admission to the hospital, the initial prerenal azotemia progressed further, causing severe reductions in renal perfusion. As a result of these, it is possible that acute renal failure due to ischemic acute tubular necrosis has developed.

Because the causes leading to prerenal azotemia (nausea, vomiting, bleeding, burns, dehydration, fluid sequestration into the third spaces) can lead to ischemic acute tubular necrosis. Both have the same spectrum (12). BUN/CRE: 89/8.9=10 at the time of first presentation of the case. This is a finding in favour of acute tubular necrosis. Because this rate is <20, it shows that it is of renal origin (13). A small amount of residual urine after urinary catheterization indicated that there was no post-renal ARF. Nausea and vomiting during emergency admission are due to uremia. He was taken to haemodialysis only 2 times, on 07-08-03.2022. With adequate hydration and hemodynamic stabilization, his clinic tended to improve. Normal urine output was achieved. In this case, diagnostic renal biopsy was not performed due to rapid improvement with emergency haemodialysis and hydration treatments. In fact, this situation also removed the diagnosis of interstitial nephritis. There was no need for steroid treatment. In the last examination of the patient who was hospitalized for 7 days and treated, Urea: 32 mg/dl, BUN: 15 mg/dl, CRE: 1.04, GFR: 74 ml/min.

CONCLUSION

The decrease in haemoglobin values may have resulted from blood loss during venous catheter insertion, repeated tests, and haemodialysis sessions (Table-1). Complaints such as nausea, vomiting, and diarrhea due to the use of Molnupiravir in patients over 65 years of age and those with chronic diseases should be seriously considered. It should be included in the category of significant side effects in phase-3 studies. This situation may cause severe dehydration and ARF in patients. The patient should definitely be informed and communicated. When necessary, the nearest health institution should be consulted. Otherwise, it may lead to increased mortality and morbidity. It may bring an additional financial burden. It should be followed closely in terms of chronic nephrotoxicity.

Author Contributions: HEY: Concept, Data collection and/or processing, Patient examination, Analysis and/or interpretation, Literature review, HEY: Writing, Revision.

Acknowledgments: None

Conflict of interest: The authors declare no competing interests.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the institutional and/or national research committee's ethical standards and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

REFERENCES

1. Vicenti I, Zuzzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat. 2021;31(4):325-337.
2. Shu B, Gong P. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation. Proc Natl Acad Sci U S A. 2016 ;12;113(28):E4005-14
3. Ghasemnejad-Berenji M, Pashaour P, Favipiravir and COVID-19: A Simplified Summary. Drug Res (Stuttg). 2021 ;71(3):166-170.
4. Imran M, Alshrahi AS, Axdag SMB, Abida. Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review. J Infect Public Health. 2021 ;14(8):1075-1086.
5. Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. Update in: Sci Transl Med. 2022 19;14(628):eaal7430
6. Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol. 2021;50:17-22

7. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, et al. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5):e02428-20.

8. MERCK. Merck and Ridgeback Biotherapeutics provide update on progress of clinical development program for molnupiravir, an investigational oral therapeutic for the treatment of mild to moderate COVID-19. Press release, provide update-on-progress-of-clinical-development-program-for molnupiravir-an-investigational-oral-therapeutic-for-the-treatment-of-mild-to-moderate-covid-19/ (Merck & Ridgeback Biotherapeutics, 15 April 2021).

9. Ridgeback’s Ma. Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study. Accessed . 2021

10. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. Ann Intern Med. 2011 20;155(6):408.

11. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 ;386(6):509-520.

12. Schrier RW, Shchekochikhin D, Ginès P. Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. Nephrol Dial Transplant. 2012 ;27(7):2625-8.

13. Agrawal M, Swartz R. Acute renal failure. Am Fam Physician. 2001;63(3):445.